255 related articles for article (PubMed ID: 29882016)
1. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Rodon J; Pérez-Fidalgo A; Krop IE; Burris H; Guerrero-Zotano A; Britten CD; Becerra C; Schellens J; Richards DA; Schuler M; Abu-Khalaf M; Johnson FM; Ranson M; Edenfield J; Silva AP; Hackl W; Quadt C; Demanse D; Duval V; Baselga J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):285-298. PubMed ID: 29882016
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Wise-Draper TM; Moorthy G; Salkeni MA; Karim NA; Thomas HE; Mercer CA; Beg MS; O'Gara S; Olowokure O; Fathallah H; Kozma SC; Thomas G; Rixe O; Desai P; Morris JC
Target Oncol; 2017 Jun; 12(3):323-332. PubMed ID: 28357727
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors.
Toyoda M; Watanabe K; Amagasaki T; Natsume K; Takeuchi H; Quadt C; Shirao K; Minami H
Cancer Chemother Pharmacol; 2019 Feb; 83(2):289-299. PubMed ID: 30446785
[TBL] [Abstract][Full Text] [Related]
5. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
Carlo MI; Molina AM; Lakhman Y; Patil S; Woo K; DeLuca J; Lee CH; Hsieh JJ; Feldman DR; Motzer RJ; Voss MH
Oncologist; 2016 Jul; 21(7):787-8. PubMed ID: 27286790
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
Wei XX; Hsieh AC; Kim W; Friedlander T; Lin AM; Louttit M; Ryan CJ
Oncologist; 2017 May; 22(5):503-e43. PubMed ID: 28314838
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
[TBL] [Abstract][Full Text] [Related]
9. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Markman B; Tabernero J; Krop I; Shapiro GI; Siu L; Chen LC; Mita M; Melendez Cuero M; Stutvoet S; Birle D; Anak Ö; Hackl W; Baselga J
Ann Oncol; 2012 Sep; 23(9):2399-2408. PubMed ID: 22357447
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
11. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
[TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
15. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
[TBL] [Abstract][Full Text] [Related]
16. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
17. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M
Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
20. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
